Colleen Kusy
Stock Analyst at Baird
(0)
# 4739
Out of 5,370 analysts
57
Total ratings
28.95%
Success rate
-16.68%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
ELVN Enliven Therapeutics | Maintains: Outperform | 40 52 | 23.07 | 125.4% | 3 | Jun 16, 2025 | |
AGEN Agenus | Maintains: Neutral | 4 6 | 5.11 | 17.42% | 4 | Jun 4, 2025 | |
APLS Apellis Pharmaceutic... | Maintains: Outperform | 55 47 | 18.32 | 156.55% | 11 | May 8, 2025 | |
OCS Oculis Holding | Maintains: Outperform | 37 41 | 19.15 | 114.1% | 4 | Mar 13, 2025 | |
CHRS Coherus BioSciences | Maintains: Outperform | 4 6 | 0.78 | 669.23% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 50 65 | 17.23 | 277.25% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 3 | n/a | n/a | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 18 17 | 8.78 | 93.62% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 27 25 | 9.43 | 165.11% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 105 | 76.36 | 37.51% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 40 | n/a | n/a | 3 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 15 | n/a | n/a | 1 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 255 210 | 4.51 | 4556.32% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 30 34 | 2.1 | 1519.05% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 230 | 1.7 | 13429.41% | 1 | Nov 2, 2021 |